# Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

> **NCT05412004** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 469 (actual)

## Conditions studied

- Obstructive Sleep Apnea
- Obesity

## Interventions

- **DRUG:** Tirzepatide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05412004
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-21
- **Primary completion:** 2024-03-12
- **Final completion:** 2024-03-29
- **Target enrollment:** 469 (ACTUAL)
- **Last updated:** 2025-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05412004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05412004, "Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05412004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*